UAE First to Approve New Breast Cancer Treatment

The Emirates Drug Establishment has approved Etcamah, a targeted therapy for advanced breast cancer patients with an ESR1 gene mutation, making the UAE the first country globally to offer this treatment option. For thousands of women whose cancer has stopped responding to hormone therapy, this approval opens a door that didn't exist anywhere else in the world until now.

The oral medication works by blocking and breaking down estrogen receptors in cancer cells that fuel tumor growth and spread. It's designed for patients with advanced or metastatic breast cancer who develop this particular mutation while undergoing hormone therapy, offering hope when other treatments stop working.

Dr. Fatima Al Kaabi, Director-General of the Emirates Drug Establishment, explained that the swift approval showcases the UAE's regulatory framework balancing speed with safety. The decision came after rigorous scientific evaluation of the drug's quality, safety, and effectiveness.

The approval drew from results of the Phase III SERENA-6 trial, which showed significant improvements in how long patients lived without their cancer worsening. These weren't just statistical wins on paper but meaningful extensions of quality time for real people facing one of the most common cancers affecting women worldwide.

Sameh El Fangary, Gulf Country President at AstraZeneca, called the UAE approval an important step toward expanding treatment options. The company developed the medication, known by its active ingredient camizestrant, as a next-generation therapy that pairs with existing cancer drugs called CDK4/6 inhibitors.

The Ripple Effect

This first-in-world approval signals a shift in how quickly breakthrough treatments can reach patients globally. By establishing itself as a trusted testing ground for pharmaceutical innovation, the UAE is creating a pathway that could accelerate access to life-saving drugs in other countries. When one nation demonstrates both the scientific rigor and regulatory agility to safely fast-track treatments, it raises the bar for healthcare systems worldwide.

The Emirates Drug Establishment emphasized that early detection, sticking to treatment plans, and regular checkups with doctors remain crucial for improving outcomes. Breast cancer continues to be one of the most common cancers among women, making each new treatment option a significant victory in the ongoing fight against the disease.

For eligible patients in the UAE, this approval means access to a therapy the rest of the world is still waiting for.